William White Net Worth

The estimated Net Worth of William Richard White is at least $7.47 million dollars as of 26 August 2024. Mr. White owns over 98,334 units of Akero Therapeutics Inc stock worth over $1,664,429 and over the last 5 years he sold AKRO stock worth over $2,281,715. In addition, he makes $3,525,820 as Chief Financial Officer et Executive Vice President and Head of Corporate Development at Akero Therapeutics Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. White AKRO stock SEC Form 4 insiders trading

William has made over 22 trades of the Akero Therapeutics Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he exercised 98,334 units of AKRO stock worth $1,584,161 on 26 August 2024.

The largest trade he's ever made was exercising 161,855 units of Akero Therapeutics Inc stock on 23 July 2024 worth over $1,134,604. On average, William trades about 15,418 units every 39 days since 2019. As of 26 August 2024 he still owns at least 64,966 units of Akero Therapeutics Inc stock.

You can see the complete history of Mr. White stock trades at the bottom of the page.

William White biography

William White J.D. serves as Chief Financial Officer, Executive Vice President and Head of Corporate Development of the Company. Mr. White has served as our Executive Vice President, Chief Financial Officer and Head of Corporate Development since April 2019. Before joining our company, Mr. White served as a Managing Director and Head of US Life Sciences Investment Banking at Deutsche Bank from September 2017 until March 2019. Prior to that position, Mr. White was a Managing Director in Healthcare Investment Banking at Citigroup from May 2006 until September 2017. Previously, he served as Vice President in Healthcare Investment Banking at Goldman, Sachs & Co., from April 2004 to March 2006. Mr. White received an A.B. from Princeton University, an M.P.P. from Harvard University and a J.D. from Columbia University.

What is the salary of William White?

As the Chief Financial Officer et Executive Vice President and Head of Corporate Development of Akero Therapeutics Inc, the total compensation of William White at Akero Therapeutics Inc is $3,525,820. There are 1 executives at Akero Therapeutics Inc getting paid more, with Andrew Cheng having the highest compensation of $5,431,810.

How old is William White?

William White is 47, he's been the Chief Financial Officer et Executive Vice President and Head of Corporate Development of Akero Therapeutics Inc since 2019. There are 12 older and 2 younger executives at Akero Therapeutics Inc. The oldest executive at Akero Therapeutics Inc is Dr. Timothy Rolph, 67, who is the Co-Founder & Chief Scientific Officer.

What's William White's mailing address?

William's mailing address filed with the SEC is 601 GATEWAY BOULEVARD, SUITE 350, SOUTH SAN FRANCISCO, CA, 94080.

Insiders trading at Akero Therapeutics Inc

Over the last 5 years, insiders at Akero Therapeutics Inc have traded over $146,260,704 worth of Akero Therapeutics Inc stock and bought 4,870,000 units worth $104,250,550 . The most active insiders traders include Group, Llc Green Jeremy Red..., Trust Blue Horizon Enterpri... et G. Walmsley Graham. On average, Akero Therapeutics Inc executives and independent directors trade stock every 11 days with the average trade being worth of $1,642,344. The most recent stock trade was executed by Jonathan Young on 3 September 2024, trading 5,000 units of AKRO stock currently worth $133,600.

What does Akero Therapeutics Inc do?

akero therapeutics is developing best-in-class medicines that restore metabolic balance to treat non-alcoholic steatohepatitis (nash) and other serious metabolic diseases. akero's lead clinical program, akr-001, is a long-acting fc fusion modified fgf21 protein and potential best-in-class treatment for nash. akr-001 builds upon two decades of work on fgf21 biology. it is designed to affect both the liver and adipose tissue, reducing liver fat and suppressing inflammation and fibrosis.

Complete history of Mr. White stock trades at Akero Therapeutics Inc

Akero Therapeutics Inc executives and stock owners

Akero Therapeutics Inc executives and other stock owners filed with the SEC include:

• Andrew Cheng,
  President, Chief Executive Officer, Director
• William White,
  Chief Financial Officer, Executive Vice President and Head of Corporate Development
• Timothy Rolph,
  Co-Founder, Chief Scientific Officer
• Jonathan Young,
  Co-Founder, Chief Operating Officer, Executive Vice President
• Dr. Andrew Cheng,
  Pres, CEO & Director
• Dr. Timothy Rolph,
  Co-Founder & Chief Scientific Officer
• Dr. Jonathan M. Young,
  Co-Founder, Exec. VP, COO & Sec.
• William R. White J.D.,
  Exec. VP, CFO, Treasurer & Head of Corp. Devel.
• Mark Iwicki,
  Independent Non-Executive Chairman of the Board
• Kevin Bitterman,
  Non-Executive Independent Director
• Seth Harrison,
  Non-Executive Independent Director
• Graham Walmsley,
  Non-Executive Independent Director
• Kitty Yale,
  Chief Development Officer
• Jane Henderson,
  Non-Executive Independent Director
• Tomas Heyman,
  Independent Director
• Kitty Yale,
  Exec. VP & Chief Devel. Officer
• John J. Schembri,
  VP of Fin. & Controller
• Venture Fund Xi, L.P. Atlas,
  10% owner
• Trust Blue Horizon Enterpri...,
  
• Venture Capital Vi, L.P.Ver...,
  
• Group, Llc Green Jeremy Red...,
  
• Global Strategic Fund Ii L....,
  
• Venture Fund Xi, L.P.Atlas ...,
  
• Aaron Royston,
  Director
• Venture Capital Vi, L.P. Ve...,
  10% owner
• Life Science Ventures, L.P....,
  
• Venture Fund Xi, L.P.Atlas ...,
  
• Venture Opportunity Fund I,...,
  10% owner
• Chou Judy,
  
• Catriona Yale,
  Chief Development Officer
• Yuan Xu,
  
• Scott A. Gangloff,
  Chief Technology Officer
• Patrick Lamy,
  Senior VP, Commercial Strategy